Jefferies Financial Group Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $3.00

Sangamo Therapeutics (NASDAQ:SGMO) had its price objective cut by research analysts at Jefferies Financial Group from $7.00 to $3.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 194.12% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, December 13th. Finally, Barclays raised their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Sangamo Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock opened at $1.02 on Tuesday. The firm has a 50-day moving average of $2.14 and a 200-day moving average of $1.22. The company has a market cap of $212.82 million, a price-to-earnings ratio of -1.36 and a beta of 1.15. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same quarter in the prior year, the business posted ($0.34) EPS. As a group, sell-side analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors have recently modified their holdings of SGMO. Meritage Portfolio Management boosted its stake in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Sangamo Therapeutics during the 3rd quarter valued at approximately $150,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.